From f887b7a5d1e1373622544668153ec8b772bd8d39 Mon Sep 17 00:00:00 2001 From: vaishnavi Date: Sat, 5 Sep 2026 11:42:57 +0200 Subject: [PATCH] Add Lung Cancer Genomic Testing Market Size, Share, Trends & Forecast --- ...ng-Market-Size%2C-Share%2C-Trends-%26-Forecast.md | 12 ++++++++++++ 1 file changed, 12 insertions(+) create mode 100644 Lung-Cancer-Genomic-Testing-Market-Size%2C-Share%2C-Trends-%26-Forecast.md diff --git a/Lung-Cancer-Genomic-Testing-Market-Size%2C-Share%2C-Trends-%26-Forecast.md b/Lung-Cancer-Genomic-Testing-Market-Size%2C-Share%2C-Trends-%26-Forecast.md new file mode 100644 index 0000000..234c03e --- /dev/null +++ b/Lung-Cancer-Genomic-Testing-Market-Size%2C-Share%2C-Trends-%26-Forecast.md @@ -0,0 +1,12 @@ +The **Lung Cancer Genomic Testing Market** is expanding as personalized medicine becomes increasingly important in the diagnosis and treatment of lung cancer. Genomic testing helps identify genetic mutations and molecular biomarkers that can assist healthcare professionals in selecting targeted therapies and developing individualized treatment strategies. + +https://www.wiseguyreports.com/reports/lung-cancer-genomic-testing-market + + +The rising incidence of lung cancer, growing adoption of precision medicine, and advancements in molecular diagnostics are key factors supporting market growth. Next-generation sequencing and other advanced genomic technologies enable the analysis of multiple genetic alterations from patient samples, supporting more comprehensive disease profiling. Increasing research and development activities are also contributing to the discovery of new biomarkers and targeted treatment opportunities. + +Pharmaceutical companies, diagnostic laboratories, hospitals, and research institutions are increasingly investing in genomic testing capabilities. Growing awareness of biomarker-driven therapies and improvements in testing accessibility are expected to create additional opportunities for market participants. + +North America represents a major market due to advanced healthcare infrastructure, strong research activity, and widespread adoption of precision oncology. Europe is also witnessing steady development, while Asia-Pacific is expected to experience promising growth as cancer diagnostics and genomic medicine become more accessible. + +Overall, advancements in sequencing technologies, increasing demand for personalized cancer care, and the development of targeted therapies are expected to drive the **Lung Cancer Genomic Testing Market** in the coming years.